mk

@RNArelics

New York, NY
Vrijeme pridruživanja: rujan 2018.

Tweetovi

Blokirali ste korisnika/cu @RNArelics

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @RNArelics

  1. proslijedio/la je Tweet
    29. sij

    And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs:

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Number of patients treated w/ CAR-Ts in Europe (commercial vs academic)

    Poništi
  3. proslijedio/la je Tweet
    30. sij

    A prime example of a great explainer for a complex topic: my brilliant friend , aka Gene Editor, explains genome editing and search-and-replace (prime) editing re:

    Poništi
  4. proslijedio/la je Tweet

    Matthew Disney is talking about how to approach RNA as a target for small-molecule probes and drugs at - here's a perspective with more on this topic

    Poništi
  5. proslijedio/la je Tweet
    28. sij

    Humira biosimilars now controlling almost 40% of the market in the EU, according to Bernstein. The UK and Germany are outpacing the others... ...and the US looks on in shame, swallowing another 7.4% price increase from AbbVie for 2020

    Prikaži ovu nit
    Poništi
  6. proslijedio/la je Tweet
    28. sij

    Biosimilar competition update: is launching its 3 at WAC list prices of -22% to -24% below competitors' products Open question: Will , , and embrace or block lower price ?

    Poništi
  7. proslijedio/la je Tweet
    28. sij

    The FDA finalized 6 guidance documents on development about: - - - Retinal disorders - CMC for INDs - LT follow-up - Retrovirus testing Also released new draft guidance on interpreting the sameness of gene therapies.

    Poništi
  8. proslijedio/la je Tweet
    28. sij

    I can see how this makes it a lot easier to read. Thank you for assembling.

    Poništi
  9. proslijedio/la je Tweet
    26. sij

    Kobe was a legend on the court and just getting started in what would have been just as meaningful a second act. To lose Gianna is even more heartbreaking to us as parents. Michelle and I send love and prayers to Vanessa and the entire Bryant family on an unthinkable day.

    Poništi
  10. proslijedio/la je Tweet
    26. sij

    Given there will be a big need for many biotech's to raise this year & January 2020 broke an all-time record for total amount raised & # of Co's that raised in Jan, I put together a list (far from perfect) of bio companies that have < 2 years of cash based on estimates.

    Poništi
  11. proslijedio/la je Tweet
    22. sij

    Woodcock to Unger to Stein, or how scored its FDA double play. Via

    Poništi
  12. proslijedio/la je Tweet

    Neutrophils as emerging therapeutic targets in infection, pulmonary diseases, cardiovascular diseases, inflammatory disorders and cancer - a new review published today

    Poništi
  13. proslijedio/la je Tweet
    22. sij

    Very underwhelming data for anti-CD47 magrolimab + cetuximab combo in colorectal cancer 6.7% (2/30) ORR in KRAS wild type CRC 0% (0/40) ORR in KRAS mutant CRC

    Poništi
  14. proslijedio/la je Tweet
    17. sij

    Loved this story from -- At , two CEOs, two radically different therapies, and a fight to chase down sickle cell

    Poništi
  15. proslijedio/la je Tweet
    13. sij

    Just amazing people are still falling for these "response" from their miracle sextuple combo How the hell do you run a controlled trial to convince FDA about the real effect of your drug?

    Poništi
  16. proslijedio/la je Tweet
    16. sij
    Poništi
  17. proslijedio/la je Tweet

    Our NEW Review by Vishwakarma & Piddini discusses how cell competition between tumour cells & neighbouring epithelial host cells may dictate tumorigenesis & proposes manipulating cell competition as an orthogonal therapeutic strategy

    Poništi
  18. proslijedio/la je Tweet
    15. sij

    This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones

    Poništi
  19. proslijedio/la je Tweet
    15. sij

    Day 2 highlights are now live, including Roche’s optimism for the future of neuroscience and Ionis on future partnerships. Catch up here:

    Poništi
  20. proslijedio/la je Tweet
    15. sij

    This is probably the most interesting stat in 2020 E&Y Firepower Report and explains the lack of M&A at "69% of surveyed dealmakers say the valuation gap between buyers and sellers is the largest its been since 2008"

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·